Phase 1 N=38 Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Under Fasting Conditions
Healthy
Primary: Maximum Plasma Concentration (Cmax) for Zolpidem Tartrate — 191.94; 193.43 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=220 MK0524B Bioequivalence Study (0524B-070)
Dyslipidemia
Primary: Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid — 9.19; 8.03 ng/mL * Hour
Phase 1 N=34 Fed Bioavailability Study of Zonisamide Capsules
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 910.95; 921.68 ng/mL
Phase 1 N=34 Fasting Bioavailability Study of Zonisamide Capsules
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 1,052.65; 1,078.46 ng/mL
Phase 1 N=54 Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 9.26; 10.01 ng/mL
Phase 1 N=27 A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2,246.58; 2,080.18; 2,278.46; 2,539.94 ng/mL
Phase 1 N=24 A Dose Proportionality Study of Quinine Sulfate Capsules Under Fasting Conditions
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2,118.35; 4,236.70; 3,242.92 ng/mL
Phase 1 N=54 Fasting Bioavailability Study of Lovastatin Tablets and Mevacor Tablets
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 1.86; 1.96 ng/mL
Phase 1 N=30 A Pharmacokinetic Study of Colchicine With an Oral Contraceptive
Pharmacokinetics
Primary: Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss) — 24.17 ng/mL
Phase 1 N=24 Infliximab (Remicade) for Patients With Acute Kawasaki Disease
Kawasaki Disease
Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events
Phase 1 N=52 Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.
Healthy
Primary: AUC(0-tz) of Unconjugated Rotigotine — 3.0168; 3.0635 (ng/ mL)*h
Phase 1 N=22 Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
Breast Neoplasms
Primary: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters — 6.0; 6.0; 6.0; 6.0 hours
Phase 1 N=28 Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Clinical Response to Photodynamic Therapy — 9; 14; 5 lesions
Phase 1 N=32 Fasted Bioavailability Study of Cilostazol Tablets, 50mg
Therapeutic Equivalency, Healthy
Primary: Maximum Plasma Concentration (Cmax) — 565.52; 570.60 ng/mL
Phase 1 N=32 Fasted Bioavailability Study of Cilostazol Tablets, 100 mg
Therapeutic Equivalency
Primary: Maximum Plasma Concentration (Cmax) — 484.895; 472.689 ng/mL